Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03034356 · ClinicalTrials.gov registry record · Phase 1
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
A Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT03034356: Completed Phase 1 study, sponsored by VA Office of Research and Development.
NCT03034356 is a Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03034356, a Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.
Interventions
- DRUG Placebo
- DRUG Levetiracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03034356
The ClinicalTrials.gov registry entry for NCT03034356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03034356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03034356 about?
NCT03034356 is a clinical study titled "Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia". This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.
What is the current status of trial NCT03034356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2018-09-01. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03034356?
The interventions under investigation include: Placebo (DRUG), Levetiracetam (DRUG).
Who is sponsoring clinical trial NCT03034356?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.